U.S. markets open in 5 hours 27 minutes
  • S&P Futures

    4,602.75
    +36.50 (+0.80%)
     
  • Dow Futures

    34,636.00
    +179.00 (+0.52%)
     
  • Nasdaq Futures

    16,321.25
    +170.75 (+1.06%)
     
  • Russell 2000 Futures

    2,222.20
    +24.90 (+1.13%)
     
  • Crude Oil

    68.58
    +2.40 (+3.63%)
     
  • Gold

    1,778.30
    +1.80 (+0.10%)
     
  • Silver

    22.80
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1321
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    1.4430
    0.0000 (0.00%)
     
  • Vix

    25.33
    +2.37 (+10.32%)
     
  • GBP/USD

    1.3280
    -0.0021 (-0.16%)
     
  • USD/JPY

    113.5270
    +0.3470 (+0.31%)
     
  • BTC-USD

    56,864.82
    +42.97 (+0.08%)
     
  • CMC Crypto 200

    1,463.01
    +20.23 (+1.40%)
     
  • FTSE 100

    7,137.27
    +77.82 (+1.10%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

CLASS ACTION UPDATE for ACAD, PRVB and OCGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / June 21, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ACAD Shareholders Click Here: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=17032&wire=1
PRVB Shareholders Click Here: https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17032&wire=1
OCGN Shareholders Click Here: https://www.zlk.com/pslra-1/ocugen-inc-information-request-form?prid=17032&wire=1

* ADDITIONAL INFORMATION BELOW *

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

ACAD Lawsuit on behalf of: investors who purchased June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline : June 21, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=17032&wire=1

According to the filed complaint, during the class period, Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Provention Bio, Inc. (NASDAQ:PRVB)

PRVB Lawsuit on behalf of: investors who purchased November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline : July 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17032&wire=1

According to the filed complaint, during the class period, Provention Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ocugen, Inc. (NASDAQ:OCGN)

OCGN Lawsuit on behalf of: investors who purchased February 2, 2021 - June 10, 2021
Lead Plaintiff Deadline : August 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ocugen-inc-information-request-form?prid=17032&wire=1

According to the filed complaint, during the class period, Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/652464/CLASS-ACTION-UPDATE-for-ACAD-PRVB-and-OCGN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders